-
These data indicated that napsin A expression may inhibit TGFbetalinduced EMT and was negatively associated with EMTmediated erlotinib resistance, suggesting that napsin A expression may improve the sensitivity of lung cancer cells to EGFRTKI through the inhibition of EMT.
-
Although napsin A is infrequently expressed in endometrial carcinomas, positive results of napsin A immunostaining in endometrial neoplasms might support the diagnosis of clear cell carcinoma when the pathologic differential diagnosis includes other histologic subtypes
-
Immunohistochemical detection of thyroid transcription factor 1, Napsin A, and P40 fragment of TP63 can be used in the subclassification of non-small cell lung carcinomas.
-
it may be useful to combine NAPA and TTF-1 for increased sensitivity in lung cancer diagnostics. There is no substantial difference between monoclonal and polyclonal p40 and between different NAPA clones, whereas there is a difference between the TTF-1 clones 8G7G3/1 and SPT24
-
To the best of our knowledge, expression of monoclonal Napsin A in lymphomas has never been reported. ALK-DLBCL should be considered in the differential diagnosis when evaluating a Napsin A-positive tumor of poorly differentiated morphology and of unknown primary
-
It is important for pathologists to be aware that breast carcinomas with apocrine features can express napsin A.
-
High Napsin A expression is associated with adenocarcinoma in non-small cell lung carcinoma.
-
Napsin-A, and Desmocollin-3 were sensitive and specific markers for the diagnosis of AC and SCC, respectively. Both markers allowed classification of 54/60 cases into either AC or SCC.
-
napsin A is aberrantly expressed in a subset of lymphomas
-
CK7, TTF-1 and napsin A are predominantly expressed in primary lung adenocarcinoma patients, with CDX-2 being inconsistently expressed.
-
The immunocytochemical expressions of napsin A and p40 in imprint cytology seem to be of great utility for the accurate histological differentiation of lung cancers.
-
Combining HNF-1beta and napsin A may distinguish clear cell carcinoma from high-grade serous carcinoma, endometrioid adenocarcinoma and metastatic Krukenberg tumors.
-
napsin A is another sensitive and specific marker for distinguishing ovarian clear cell tumors (especially adenocarcinomas) from other ovarian tumors
-
Napsin A is expressed in a broad spectrum of renal neoplasms.
-
Low expression levels of NAPSA is associated with lung adenocarcinoma.
-
In diagnosis of ovarian clear cell carcinoma, Napsin A is specific but of intermediate sensitivity.
-
Napsin A is frequently expressed in ovarian and endometrial clear cell carcinomas.
-
Data indicate that polyclonal but not monoclonal napsin A antibody has a virtually universal nonspecific labeling in mucinous adenocarcinomas of various sites.
-
These data suggest that napsin A may be a useful marker for identifying metastatic adenocarcinomas of pulmonary origin
-
Our study showed that napsin A is an extremely sensitive (100%) marker of ovarian clear cell carcinomas
